The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial
Kroiss, R.; Fentiman, I. S.; Helmond, F. A.et al.
2005 • In BJOG: An International Journal of Obstetrics and Gynaecology, 112 (2), p. 228-233
[en] Objective To assess the effects of tibolone on climacteric symptoms, endometrium and serum lipid/lipoproteins in postmenopausal women receiving tamoxifen after surgery for breast cancer. Design Double-blind, randomised, placebo-controlled, multicentre pilot study. Setting Hospital outpatient clinic. Sample Seventy postmenopausal women receiving tamoxifen following surgery for early breast cancer. Methods Women received 20 mg/day oral tamoxifen plus either 2.5 mg/day oral tibolone or placebo for 12 months. Main outcome measures Frequency and severity of hot flushes (diary cards); intensity of hot flushes and sweats (Landgren scale); interference of hot flushes and sweats with normal life; frequency and intensity of other climacteric symptoms; endometrial thickness and histology; vaginal bleeding; breast cancer recurrence and serum lipid/lipoproteins. Results Daily card data showed no change in the daily number of hot flushes with either tibolone or placebo (P= 0.219) after three months. There was a significant reduction in the severity of flushes with tibolone compared with placebo (-0.4 vs 0.2, P= 0.031). The Landgren scale showed a mean change in the number of hot flushes of -0.6 with tibolone and +1.1 with placebo after 12 months (P= 0.022). Endometrial biopsies were normal and vaginal bleeding was similar in both groups. A significant decrease in triglycerides (-23%vs 1.4%) and HDL (-12%vs 19%) was seen with tibolone compared with placebo after 12 months. Conclusion Tibolone prevented an increase in hot flushes in postmenopausal women given tamoxifen following surgery for breast cancer without untoward effects on the endometrium. Beneficial effects on serum lipid profile were noted.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Kroiss, R.
Fentiman, I. S.
Helmond, F. A.
Rymer, J.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Bundred, N.
Mol-Arts, M.
Kubista, E.
Language :
English
Title :
The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial
Publication date :
February 2005
Journal title :
BJOG: An International Journal of Obstetrics and Gynaecology
Fentiman IS, Howell A, Hamed H, et al. A controlled trial of adjuvant tamoxifen, with or without prednisolone, in postmenopausal women with operable breast cancer. Br J Cancer 1994;70:729-731.
Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508.
O'Meara ES, Rossing MA, Dalling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-762.
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?) a randomised comparison: trial stopped. Lancet 2004;363:453-455.
Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106(Suppl 19):1-21.
Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-238.
Markiewicz L, Gurpride E. In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990;35:535-541.
Gusberg SB. Tamoxifen for breast cancer: associated endometrial cancer. Cancer 1990;65:1463-1464.
van Leeuwen FF, Benraadt J, Coeberger WW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
Gompel A, Chaouat M, Jacob D, Perrot J-Y, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-359.
Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617-623.
Cline JM, Anthony MS, Register TC, Borgerink H, Clarkson TB. Tibolone does not stimulate the endometrium or breast in cynomolgus monkeys. FASEB J 2001;15:A594.
Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311-318.
Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
Collins A, Landgren BM. Psychosocial factors associated with the use of hormonal replacement therapy in a longitudinal follow-up of Swedish women. Maturitas 1997;28:1-9.
Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. Br J Obstet Gynaecol 2002;109:1109-1114.
Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-1847.
Ginsburg J, Prelevic G. Tibolone in postmenopausal women with a history of breast carcinoma. J Br Menopause Soc 1995;1:24-25.
Dören M, Rübig A, Coelingh Bennink HJT, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299-306.
Huber J, Palacios S, Berglund L, et al. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886-893.
Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904-911.
Lundström E, Christow A, Svane G, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 2002;186:717-722.
Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest 2000;20:101-107.
Erel CT, Esen G, Seyisoglu H, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151-157.
Colacurci N, Fornaro F, de Franciscis P, Palermo M, del Vecchio E. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159-164.
Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165-171.
Kavanagh AM, Mitichell H, Giles GG. Hormone replacement therapy and accuracy of mammographic screening. Lancet 2000;355:270-274.
Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
Speroff L. The Million Women Study and breast cancer. Maturitas 2003;46:1-6.
Olson H. What can we learn from the Million Women Study. Maturitas 2003;46:1-6.
Velthuis-te Wierik EJM, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies (CEPT): a UK Mediplus Study. Climacteric 2004. In press.
Allen DS, de Vries C, Farmer DT. Pharmaceutical content and regimen of hormone replacement therapy and risk of breast cancer. Pharmacoepidemiol Drug Saf 2002;1(Suppl 1):296-298.
Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon J. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and can evaluation of the role of endometrial screening. J Clin Oncol 1999;17:2050-2054.
